{
  "id": "f4bf9183-7176-4087-b52d-01f815cf04db",
  "title": "Glenmark Pharma launches lung cancer treatment drug Tevimbra in India",
  "link": "https://www.business-standard.com/companies/news/glenmark-pharma-launches-lung-cancer-treatment-drug-tevimbra-in-india-125062401161_1.html",
  "description": "Tevimbra is developed by BeiGene (now BeOne Medicines), a global oncology leader. This launch marks Glenmark's first foray into immune-oncology in India",
  "author": "",
  "published": "Tue, 24 Jun 2025 21:28:55 +0530",
  "source": "https://www.business-standard.com/rss/home_page_top_stories.rss",
  "categories": null,
  "byline": "Press Trust of India",
  "length": 2519,
  "excerpt": "Glenmark Pharmaceuticals on Tuesday said it has launched the lung cancer treatment drug Tevimbra in India, following the approval by the Central Drugs Standard Control Organisation.",
  "siteName": "Business Standard",
  "favicon": "https://www.business-standard.com/android-chrome-192x192-min.png",
  "text": "Tevimbra is developed by BeiGene (now BeOne Medicines), a global oncology leader. This launch marks Glenmark's first foray into immune-oncology in India\"At a time when the cancer burden is rising sharply, we are proud to enable oncologists and patients to access Tevimbra, a therapy with proven efficacy and safety outcomes, strong science, and meaningful impact,\" Glenmark Pharmaceuticals President and Business Head India Formulations Alok Malik said. | Image: XPress Trust of India New Delhi 2 min read Last Updated : Jun 24 2025 | 9:28 PM ISTListen to This Article Glenmark Pharmaceuticals on Tuesday said it has launched the lung cancer treatment drug Tevimbra in India, following the approval by the Central Drugs Standard Control Organisation. Tevimbra is developed by BeiGene (now BeOne Medicines), a global oncology leader. This launch marks Glenmark's first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio, the company said in a regulatory filing.  ALSO READ: Novo Nordisk launches Wegovy in India to rival Eli Lilly's weight-loss drug \"At a time when the cancer burden is rising sharply, we are proud to enable oncologists and patients to access Tevimbra, a therapy with proven efficacy and safety outcomes, strong science, and meaningful impact,\" Glenmark Pharmaceuticals President and Business Head India Formulations Alok Malik said. Immuno-oncology offers a promising future for the treatment of various types of advanced cancers, which are difficult to treat, he said, adding that \"Our foray in this area marks a significant inflection point in our journey to build a world-class oncology portfolio that is innovative, inclusive and at the same time life-changing for patients\". Tevimbra is indicated for the treatment of first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy and second-line treatment of locally advanced or metastatic NSCLC and oesophagal squamous cell carcinoma (ESCC) as monotherapy, the company said. It is approved and marketed in multiple leading global markets, including the United States, European Union, Australia and China.(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)More From This SectionDon't miss the most important news and views of the day. Get them on our Telegram channelFirst Published: Jun 24 2025 | 9:28 PM IST",
  "image": "https://bsmedia.business-standard.com/_media/bs/img/article/2025-03/12/thumb/featurecrop/1200X630/1741764185-3081.jpg",
  "html": "\u003cdiv id=\"readability-page-1\" class=\"page\"\u003e\u003cdiv\u003e\u003ch2\u003eTevimbra is developed by BeiGene (now BeOne Medicines), a global oncology leader. This launch marks Glenmark\u0026#39;s first foray into immune-oncology in India\u003c/h2\u003e\u003cdiv\u003e\u003cdiv\u003e\u003cp\u003e\u003ci\u003e\u003c/i\u003e\u003cimg src=\"https://bsmedia.business-standard.com/_media/bs/img/article/2025-03/12/full/1741764185-3081.jpg?im=FeatureCrop,size=(826,465)\" title=\"Glenmark, Glenmark Pharmaceuticals\" alt=\"Glenmark, Glenmark Pharmaceuticals\" width=\"826\" height=\"465\"/\u003e\u003c/p\u003e\u003c/div\u003e\u003cp\u003e\u0026#34;At a time when the cancer burden is rising sharply, we are proud to enable oncologists and patients to access Tevimbra, a therapy with proven efficacy and safety outcomes, strong science, and meaningful impact,\u0026#34; Glenmark Pharmaceuticals President and Business Head India Formulations Alok Malik said. | Image: X\u003c/p\u003e\u003c/div\u003e\u003cp\u003e\u003cspan\u003e\u003ca href=\"https://www.business-standard.com/author/press-trust-of-india\"\u003e\u003cspan\u003ePress Trust of India\u003c/span\u003e\u003c/a\u003e\u003cspan\u003e New Delhi \u003c/span\u003e\u003c/span\u003e\u003c/p\u003e\u003cdiv\u003e\u003cp\u003e2 min read  Last Updated : Jun 24 2025 | 9:28 PM IST\u003c/p\u003e\u003c/div\u003e\u003cdiv\u003e\u003ch4\u003eListen to This Article\u003c/h4\u003e\u003c/div\u003e\u003cdiv\u003e\u003cdiv id=\"parent_top_div\"\u003e\u003cp\u003e\n\tGlenmark Pharmaceuticals on Tuesday said it has launched the lung cancer treatment drug Tevimbra in India, following the approval by the Central Drugs Standard Control Organisation.\u003c/p\u003e\n\u003cp\u003e\n\tTevimbra is developed by BeiGene (now BeOne Medicines), a global oncology leader. This launch marks Glenmark\u0026#39;s first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio, the company said in a regulatory filing.\u003csmall\u003e \u003c/small\u003e\n\t\u003cstrong\u003eALSO READ: \u003ca href=\"https://www.business-standard.com/companies/news/novo-nordisk-launches-wegovy-in-india-challenges-eli-lilly-mounjaro-125062401125_1.html\" target=\"_blank\"\u003eNovo Nordisk launches Wegovy in India to rival Eli Lilly\u0026#39;s weight-loss drug\u003c/a\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\n\t\u0026#34;At a time when the cancer burden is rising sharply, we are proud to enable oncologists and patients to access Tevimbra, a therapy with proven efficacy and safety outcomes, strong science, and meaningful impact,\u0026#34; Glenmark Pharmaceuticals President and Business Head India Formulations Alok Malik said.\u003c/p\u003e\n\u003cp\u003e\n\tImmuno-oncology offers a promising future for the treatment of various types of advanced cancers, which are difficult to treat, he said, adding that \u0026#34;Our foray in this area marks a significant inflection point in our journey to build a world-class oncology portfolio that is innovative, inclusive and at the same time life-changing for patients\u0026#34;.\u003c/p\u003e\n\n\u003cp\u003e\n\tTevimbra is indicated for the treatment of first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy and second-line treatment of locally advanced or metastatic NSCLC and oesophagal squamous cell carcinoma (ESCC) as monotherapy, the company said.\u003c/p\u003e\n\u003cp\u003e\n\tIt is approved and marketed in multiple leading global markets, including the United States, European Union, Australia and China.\u003c/p\u003e\u003c/div\u003e\u003cp id=\"auto_disclaimer\"\u003e(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)\u003c/p\u003e\u003cdiv\u003e\u003cp\u003e\u003ch3\u003e\u003cspan\u003eMore From This Section\u003c/span\u003e\u003c/h3\u003e\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cp\u003e\u003ca href=\"https://t.me/bsindiaofficial\" target=\"_blank\"\u003eDon\u0026#39;t miss the most important news and views of the day. Get them on our  \u003csvg style=\"margin:0px 4px 0px 6px;transform:translate(-1px, 5px)\" width=\"20\" height=\"20\" viewBox=\"0 0 32 32\" fill=\"none\" xmlns=\"http://www.w3.org/2000/svg\"\u003e\u003ccircle cx=\"16\" cy=\"16\" r=\"16\" fill=\"#22A7E9\"\u003e\u003c/circle\u003e\u003cpath fill-rule=\"evenodd\" clip-rule=\"evenodd\" d=\"M21.3427 10.0889C21.5394 10.0102 21.7547 9.98303 21.9662 10.0103C22.1777 10.0375 22.3777 10.1182 22.5453 10.2439C22.7129 10.3696 22.842 10.5357 22.9192 10.725C22.9964 10.9143 23.0188 11.1197 22.9842 11.32L21.1787 21.736C21.0035 22.7407 19.8445 23.3169 18.8757 22.8164C18.0653 22.3977 16.8616 21.7526 15.779 21.0795C15.2376 20.7426 13.5794 19.6637 13.7832 18.8959C13.9583 18.2395 16.7446 15.7728 18.3367 14.3062C18.9616 13.73 18.6766 13.3976 17.9387 13.9276C16.1053 15.2435 13.1639 17.2446 12.1911 17.8079C11.3329 18.3046 10.8855 18.3894 10.3506 18.3046C9.37458 18.1502 8.46945 17.9109 7.7307 17.6194C6.73243 17.2257 6.78099 15.9204 7.72991 15.5403L21.3427 10.0889Z\" fill=\"white\"\u003e\u003c/path\u003e\u003c/svg\u003e Telegram channel\u003c/a\u003e\u003c/p\u003e\u003cp\u003eFirst Published: Jun 24 2025 | 9:28 PM IST\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e",
  "readingTime": "3 min read",
  "publishedTime": "2025-06-24T21:28:55+05:30",
  "modifiedTime": null
}
